Lisinopril vs. Losartan: Differential Effects on Urinary Sodium Excretion

Lisinopril (ACE inhibitor) increases urinary sodium excretion; losartan (ARB) does not significantly.

Mechanistic Basis

  • ACEi (lisinopril): Blocks Ang I → Ang II conversion → ↓ Ang II + ↑ bradykinin.
    • ↓ Ang II → ↓ aldosterone → ↓ distal Na⁺ reabsorption (ENaC).
    • ↑ Bradykinin → ↑ NO/prostanoids → ↑ renal blood flow, ↓ proximal reabsorption.
    • Net: Natriuresis, especially with volume expansion/heart failure.
  • ARB (losartan): Blocks AT₁ receptor only.
    • ↑ Ang II levels (unopposed AT₂ stimulation → vasodilation, natriuresis? — weak in humans).
    • No bradykinin accumulation.
    • Net: Minimal acute natriuresis; chronic Na⁺ balance via hemodynamic effects.

Clinical Implications

  • ACEi preferred in heart failure with volume overload (natriuretic synergy with loop diuretics).
  • ARB alternative if ACEi cough/angioedema; similar BP/renal outcomes.
  • Both require K⁺/Cr monitoring (hyperkalemia risk, especially with K⁺-sparing agents).

Evidence

Multiple trials (SOLVD, ATLAS, RENAAL, IDNT) confirm ACEi natriuretic effect; ARBs show less pronounced acute sodium excretion.

Urinary Disorders - Related Articles